|
1
|
Valensi P and Picard S: Lipids,
lipid-lowering therapy and diabetes complications. Diabetes Metab.
37:15–24. 2011. View Article : Google Scholar
|
|
2
|
Yee HS and Fong NT: Atorvastatin in the
treatment of primary hypercholesterolemia and mixed dyslipidemias.
Ann Pharmacother. 32:1030–1043. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Colhoun HM, Betteridge DJ, Durrington PN,
et al: Primary prevention of cardiovascular disease with
atorvastatin in type 2 diabetes in the Collaborative Atorvastatin
Diabetes Study (CARDS): multicentre randomised placebo-controlled
trial. Lancet. 364:685–696. 2004. View Article : Google Scholar
|
|
4
|
Zhou Q and Liao JK: Pleiotropic effects of
statins. Basic research and clinical perspectives. Circ J.
74:818–826. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Birnbaum Y and Ye Y: Pleiotropic effects
of statins: the role of eicosanoid production. Curr Atheroscler
Rep. 14:135–139. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Qu HY, Xiao YW, Jiang GH, Wang ZY, Zhang Y
and Zhang M: Effect of atorvastatin versus rosuvastatin on levels
of serum lipids, inflammatory markers and adiponectin in patients
with hypercholesterolemia. Pharm Res. 26:958–964. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Krysiak R, Labuzek K and Okopień B: Effect
of atorvastatin and fenofibric acid on adipokine release from
visceral and subcutaneous adipose tissue of patients with mixed
dyslipidemia and normolipidemic subjects. Pharmacol Rep.
61:1134–1145. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ricci R and Bevilacqua F: The potential
role of leptin and adiponectin in obesity: a comparative review.
Vet J. 191:292–298. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Reddy KJ, Singh M, Bangit JR and Batsell
RR: The role of insulin resistance in the pathogenesis of
atherosclerotic cardiovascular disease: an updated review. J
Cardiovasc Med (Hagerstown). 11:633–647. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Jung CH, Rhee EJ, Choi JH, et al: The
relationship of adiponectin/leptin ratio with homeostasis model
assessment insulin resistance index and metabolic syndrome in
apparently healthy Korean male adults. Korean Diabetes J.
34:237–243. 2010. View Article : Google Scholar
|
|
11
|
Kajikawa Y, Ikeda M, Takemoto S, Tomoda J,
Ohmaru N and Kusachi S: Association of circulating levels of leptin
and adiponectin with metabolic syndrome and coronary heart disease
in patients with various coronary risk factors. Int Heart J.
52:17–22. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Dubey L and Hesong Z: Role of leptin in
atherogenesis. Exp Clin Cardiol. 11:269–275. 2006.PubMed/NCBI
|
|
13
|
Wang WQ, Zhang HF, Gao GX, Bai QX, Li R
and Wang XM: Adiponectin inhibits hyperlipidemia-induced platelet
aggregation via attenuating oxidative/nitrative stress. Physiol
Res. 60:347–354. 2011.PubMed/NCBI
|
|
14
|
Plant S, Shand B, Elder P and Scott R:
Adiponectin attenuates endothelial dysfunction induced by oxidised
low-density lipoproteins. Diab Vasc Dis Res. 5:102–108. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhao SP and Wu ZH: Atorvastatin reduces
serum leptin concentration in hypercholesterolemic rabbits. Clin
Chim Acta. 360:133–140. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
von Eynatten M, Schneider JG,
Hadziselimovic S, et al: Adipocytokines as a novel target for the
anti-inflammatory effect of atorvastatin in patients with type 2
diabetes. Diabetes Care. 28:754–755. 2005.PubMed/NCBI
|
|
17
|
Blanco-Colio LM, Martín-Ventura JL,
Gómez-Guerrero C, et al: Adiponectin plasma levels are increased by
atorvastatin treatment in subjects at high cardiovascular risk. Eur
J Pharmacol. 586:259–265. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Alomari MA, Keewan EF, Qhatan R, et al:
Blood pressure and circulatory relationships with physical activity
level in young normotensive individuals: IPAQ validity and
reliability considerations. Clin Exp Hypertens. 33:345–353. 2011.
View Article : Google Scholar
|
|
19
|
Gharibeh MY, Al Tawallbeh GM, Abboud MM,
Radaideh A, Alhader AA and Khabour OF: Correlation of plasma
resistin with obesity and insulin resistance in type 2 diabetic
patients. Diabetes Metab. 36:443–449. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Matthews DR, Hosker JP, Rudenski AS,
Naylor BA, Treacher DF and Turner RC: Homeostasis model assessment:
insulin resistance and beta-cell function from fasting plasma
glucose and insulin concentrations in man. Diabetologia.
28:412–419. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bonora E, Formentini G, Calcaterra F, et
al: HOMA-estimated insulin resistance is an independent predictor
of cardiovascular disease in type 2 diabetic subjects: prospective
data from the Verona Diabetes Complications Study. Diabetes Care.
25:1135–1141. 2002. View Article : Google Scholar
|
|
22
|
Yoshitomi Y, Ishii T, Kaneki M, et al:
Relationship between insulin resistance and effect of atorvastatin
in non-diabetic subjects. J Atheroscler Thromb. 12:9–13. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kosmidou M, Hatzitolios AI, Molyva D, et
al: An association study between catalase −262C>T gene
polymorphism, sodium-lithium countertransport activity, insulin
resistance, blood lipid parameters and their response to
atorvastatin, in Greek dyslipidaemic patients and normolipidaemic
controls. Free Radic Res. 43:385–389. 2009.
|
|
24
|
Paolisso G, Barbagallo M, Petrella G, et
al: Effects of simvastatin and atorvastatin administration on
insulin resistance and respiratory quotient in aged dyslipidemic
non-insulin dependent diabetic patients. Atherosclerosis.
150:121–127. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Koh KK, Quon MJ, Han SH, Lee Y, Kim SJ and
Shin EK: Atorvastatin causes insulin resistance and increases
ambient glycemia in hypercholesterolemic patients. J Am Coll
Cardiol. 55:1209–1216. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Koh KK, Quon MJ, Han SH, et al:
Differential metabolic effects of pravastatin and simvastatin in
hypercholesterolemic patients. Atherosclerosis. 204:483–490. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Koh KK, Quon MJ, Han SH, et al: Additive
beneficial effects of fenofibrate combined with atorvastatin in the
treatment of combined hyperlipidemia. J Am Coll Cardiol.
45:1649–1653. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kumada M, Kihara S, Sumitsuji S, et al:
Association of hypoadiponectinemia with coronary artery disease in
men. Arterioscler Thromb Vasc Biol. 23:85–89. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chu CH, Lee JK, Lam HC, et al:
Atorvastatin does not affect insulin sensitivity and the
adiponectin or leptin levels in hyperlipidemic type 2 diabetes. J
Endocrinol Invest. 31:42–47. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Nakamura Y, Shimada K, Fukuda D, et al:
Implications of plasma concentrations of adiponectin in patients
with coronary artery disease. Heart. 90:528–533. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Koebnick C, Roberts CK, Shaibi GQ, et al:
Adiponectin and leptin are independently associated with insulin
sensitivity, but not with insulin secretion or beta-cell function
in overweight Hispanic adolescents. Horm Metab Res. 40:708–712.
2008.PubMed/NCBI
|
|
32
|
Zhuo Q, Wang Z, Fu P, et al: Comparison of
adiponectin, leptin and leptin to adiponectin ratio as diagnostic
marker for metabolic syndrome in older adults of Chinese major
cities. Diabetes Res Clin Pract. 84:27–33. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Alikaşifoğlu A, Gönç N, Özön ZA, Sen Y and
Kandemir N: The relationship between serum adiponectin, tumor
necrosis factor-alpha, leptin levels and insulin sensitivity in
childhood and adolescent obesity: adiponectin is a marker of
metabolic syndrome. J Clin Res Pediatr Endocrinol. 1:233–239.
2009.
|
|
34
|
Steinberger J, Moorehead C, Katch V and
Rocchini AP: Relationship between insulin resistance and abnormal
lipid profile in obese adolescents. J Pediatr. 126:690–695. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Vasques AC, Rosado LE, Rosado GP, et al:
Plasmatic lipid profile indicators related to insulin resistance.
Rev Assoc Med Bras. 55:342–346. 2009.(In Portuguese).
|
|
36
|
Sattar N, Preiss D, Murray HM, et al:
Statins and risk of incident diabetes: a collaborative
meta-analysis of randomised statin trials. Lancet. 375:735–742.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Thongtang N, Ai M, Otokozawa S, et al:
Effects of maximal atorvastatin and rosuvastatin treatment on
markers of glucose homeostasis and inflammation. Am J Cardiol.
107:387–392. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Navarese EP, Buffon A, Andreotti F, et al:
Meta-analysis of impact of different types and doses of statins on
new-onset diabetes mellitus. Am J Cardiol. 111:1123–1130. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Waters DD, Ho JE, Boekholdt SM, et al:
Cardiovascular event reduction versus new-onset diabetes during
atorvastatin therapy: effect of baseline risk factors for diabetes.
J Am Coll Cardiol. 61:148–152. 2013. View Article : Google Scholar
|
|
40
|
Preiss D, Seshasai SR, Welsh P, et al:
Risk of incident diabetes with intensive-dose compared with
moderate-dose statin therapy: a meta-analysis. JAMA. 305:2556–2564.
2011. View Article : Google Scholar : PubMed/NCBI
|
